Improves skin elasticity and enhances overall cell health with added B vitamins, Vitamin D3, E, Zinc, and Selenium
A phase I trial involving 40 patients with relapsed/refractory HL that the combination of Vorinostat (300 mg/day orally) with sirolimus (4 mg/day orally, n=22) or Everolimus (5-10 mg/day dose escalation, n=18) yielded ORR of 55% and 33%, respectively, with a median progression-free survival (PFS) of 5.8 months, suggesting synergistic efficacy of HDACi combined with mTOR inhibitors (90)
The activity of IDO is up-regulated by IFN-, IFN-, IL-1, IL-6, IL-18 and TNF-, and inhibited by anti-inflammatory cytokine IL-4 [94,95,96,97]
This helps create new cell energy